Loading company…
POSVAX develops preventive vaccines and other therapies using virus-like particle technology.
Established in 2018 and based in Seoul, South Korea, POSVAX develops vaccines for cervical cancer, head and neck cancer, RSV, and Alzheimer's disease using its virus-like particle platform. The company conducted a preclinical trial of a 9-valent HPV vaccine in 2019. It raised KRW 5000 in Series A funding in August 2019 and KRW 16000 in Series B funding in January 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in